Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 151

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 151
---
ilience and/or Nolazol; •the cost of filing and prosecuting patent applications and the cost of defending NLS’s patents; •the cost of prosecuting patent infringement actions against third parties; •development of other early -stagedevelopment product candidates; •the costs associated with commercializing Quilience and/or Nolazol if NLS receives marketing approval, including the cost and timing of establishing sales and marketing capabilities to market and sell Quilience and/or Nolazol; •subject to receipt of marketing approval, revenue received from sales of approved products, if any, in the future; •any product liability or other lawsuits related to NLS’s products; •the expenses needed to attract and retain skilled personnel; and •the costs associated with being a public company. Any additional fundraising efforts may divert its management from their day -to-dayactivities, which may adversely affect its ability to develop and commercialize its product candidates. In addition, NLS cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of its securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of its NLS Common Shares or its publicly traded Warrants to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and NLS may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact its ability to conduct its business. NLS could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and NLS may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on its business, operating results and prospects. Even if NLS believes that it has sufficient funds for its current or future operating plans, NLS may seek additional capital if market conditions are favorable or if NLS has specific strategic considerations. If NLS is unable to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the development or commercialization, if any, of any product candidates or be unable to expand its